

## Regulating the Drug Industry

### Why in news?

\n\n

\n

- Indian government may bring in a legal framework under which doctors will have to prescribe generic medicines.

\n

- It is the Government's responsibility that everyone should get health services at minimal price.

\n

\n\n

### What is the importance of the issue?

\n\n

\n

- It is a noble intention and indeed the responsibility of the government to make healthcare accessible and affordable to all.

\n

- A landmark act introduced in the US in 1984, "the Drug Price Competition and Patent Term Restoration Act" transformed the drug market in that country by allowing a generic medicine.

\n

- The generic drug would not have to undergo a complete clinical trial to be proved equivalent.

\n

- Subsequently, this model has been followed in other countries and today most OECD and other developing countries accept the substitution of a branded medicine with a generic equivalent.

\n

\n\n

### What is the need for a regulator in Drug industry?

\n\n

\n

- The argument is that the need for a muscular drug regulatory authority

(DRA) is far more urgent.

\n

- The DRA should serve the dual purpose of making the rules simpler yet stricter, while having the required resources to enforce them effectively.

\n

- Every drug manufacturer should publish details of its manufacturing facilities, specifications, capacity, certifications, all subsequent inspection reports to a central portal.

\n

- Products should be approved as generics based on whether they are pharmaceutically equivalent, bio-available, and bio-equivalent.

\n

- All new products or new combinations of existing products should be subjected to a more extensive clinical study to prove safety as well as effectiveness.

\n

- Facilities which do not comply with GMP (Good manufacturing Practice) should be immediately barred from production until such compliances are in place and products made in such a facility should be immediately recalled.

\n

- All products should be tagged with a unique RFID, barcode or such similar identification to ensure traceability from manufacture to consumption.

\n

- Generics should be labelled and sold as such in order to prevent a brand to brand substitution rather than a brand to generic substitution at the retail level.

\n

\n\n

## **What are the steps taken by the government?**

\n\n

\n

- The Ministry of Health and Family Welfare proposed the setting up of an e-portal to track and regulate the sale of drugs across the retail chain.

\n

- The aim was to prevent the sale of fake and substandard drugs, which are estimated to account for a substantial share of India's drug market.

\n

- The Ministry's proposal to bring both traditional and e-pharmacies under the ambit of the e-portal to track drugs is a welcome move.

\n

- It has mandated that e-pharmacies must set up a "licensed brick and mortar facility" as part of their operations to comply with the new regulations.

\n

\n\n

## **What is the way forward?**

\n\n

\n

- The risks associated with e-pharmacies, especially when it comes to the dispensation of prescription drugs without the necessary checks, cannot be taken lightly.

\n

- The Ministry's plan on regulating e-pharmacies is a rather outdated one.

\n

- This seems like an indirect way of delegitimising the business model of e-pharmacies, rather than a regulation that aims to improve their transparency and regulation.

\n

- The huge potential for e-commerce in the retail drugs industry is enough reason to avoid such unreasonably stringent standards.

\n

- Enforced with punitive fines for non-compliance, the new measures will not only make medicines affordable to all, but also give the customers the choice without fear of compromising the quality of their care.

\n

\n\n

\n\n

**Source: Business Line**

\n



**SHANKAR**  
**IAS PARLIAMENT**  
*Information is Empowering*